GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vascular Biogenics Ltd (NAS:VBLT) » Definitions » Shiller PE Ratio

Vascular Biogenics (Vascular Biogenics) Shiller PE Ratio : (As of May. 12, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Vascular Biogenics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Vascular Biogenics Shiller PE Ratio Historical Data

The historical data trend for Vascular Biogenics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vascular Biogenics Shiller PE Ratio Chart

Vascular Biogenics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vascular Biogenics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vascular Biogenics's Shiller PE Ratio

For the Biotechnology subindustry, Vascular Biogenics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vascular Biogenics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vascular Biogenics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Vascular Biogenics's Shiller PE Ratio falls into.



Vascular Biogenics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Vascular Biogenics's E10 for the quarter that ended in Jun. 2023 is calculated as:

For example, Vascular Biogenics's adjusted earnings per share data for the three months ended in Jun. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-0.01/128.7287*128.7287
=-0.010

Current CPI (Jun. 2023) = 128.7287.

Vascular Biogenics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201309 -0.379 98.790 -0.494
201312 -0.449 98.326 -0.588
201403 -0.419 99.695 -0.541
201406 -0.200 100.560 -0.256
201409 -2.450 100.428 -3.140
201412 -0.258 99.070 -0.335
201503 -0.150 99.621 -0.194
201506 -0.150 100.684 -0.192
201509 -0.290 100.392 -0.372
201512 -0.140 99.792 -0.181
201603 -0.210 100.470 -0.269
201606 -0.140 101.688 -0.177
201609 -0.120 101.861 -0.152
201612 -0.180 101.863 -0.227
201703 -0.190 102.862 -0.238
201706 -0.180 103.349 -0.224
201709 -0.240 104.136 -0.297
201712 0.240 104.011 0.297
201803 -0.240 105.290 -0.293
201806 -0.130 106.317 -0.157
201809 -0.150 106.507 -0.181
201812 -0.100 105.998 -0.121
201903 -0.120 107.251 -0.144
201906 -0.130 108.070 -0.155
201909 -0.140 108.329 -0.166
201912 -0.160 108.420 -0.190
202003 -0.150 108.902 -0.177
202006 -0.140 108.767 -0.166
202009 -0.120 109.815 -0.141
202012 -0.150 109.897 -0.176
202103 -0.120 111.754 -0.138
202106 -0.120 114.631 -0.135
202109 -0.090 115.734 -0.100
202112 -0.120 117.630 -0.131
202203 -0.130 121.301 -0.138
202206 -0.120 125.017 -0.124
202209 -0.120 125.227 -0.123
202212 -0.050 125.222 -0.051
202303 -0.030 127.348 -0.030
202306 -0.010 128.729 -0.010

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vascular Biogenics  (NAS:VBLT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Vascular Biogenics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Vascular Biogenics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vascular Biogenics (Vascular Biogenics) Business Description

Traded in Other Exchanges
N/A
Address
8 HaSatat Street, Modi’in, ISR, 7178106
Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.
Executives
Builders Vc Fund I, L.p. 10 percent owner 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
James Jimin Kim 10 percent owner C/O NOTABLE LABS, INC., 320 HATCH DRIVE, FOSTER CITY CA 94404
B Capital Group Management, L.p. 10 percent owner 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
B Capital Group Investors Ii Ltd. 10 percent owner 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
B Capital Group Partners Ii, L.p. 10 percent owner 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
Joseph P Wagner officer: Chief Scientific Officer 320 HATCH DRIVE, FOSTER CITY CA 94404
Tuomo Patsi director 320 HATCH DRIVE, FOSTER CITY NY 94404
Thomas Bock director, officer: Chief Executive Officer 320 HATCH DRIVE, FOSTER CITY NY 94404
Michele Galen director 320 HATCH DRIVE, FOSTER CITY CA 94404
Fr Capital Holdings, L.p. 10 percent owner 2400 MARKET STREET, SUITE 237, PHILADELPHIA PA 19103
B Capital Fund Ii, L.p. 10 percent owner C/O B CAPITAL GROUP MANAGEMENT, L.P., 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
Builders Vc Fund I (canada), L.p. 10 percent owner 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
Builders Vc Entrepreneurs Fund I, L.p. 10 percent owner 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
Dubin Thomas I H director C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Peter Feinberg director C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142